Hypoxia signaling: Challenges and opportunities for cancer therapy

被引：31
|
作者：
Ivan, Mircea [1 ,2 ]
Fishel, Melissa L. [3 ,4 ]
Tudoran, Oana M. [5 ]
Pollok, Karen E. [3 ]
Wu, Xue [6 ]
Smith, Paul J. [7 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA
[3] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN USA
[4] IU Simon Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN USA
[5] Oncol Inst Prof Dr Ion Chiricuta, Cluj Napoca, Cluj, Romania
[6] Ohio State Univ, Columbus, OH USA
[7] Cardiff Univ, Sch Med, Cardiff, Wales
来源：
SEMINARS IN CANCER BIOLOGY | 2022年 / 85卷
关键词：
Hypoxia; HIF1; HIF2; HIF inhibitors; Hypoxia-activated prodrug; SMALL-MOLECULE INHIBITOR; ANTI-ANGIOGENIC THERAPY; DNA TOPOISOMERASE-II; CYTOCHROMES P450 CYP; RENAL-CELL CARCINOMA; INDUCIBLE FACTOR; ACTIVATED PRODRUG; N-OXIDE; HEPATOCELLULAR-CARCINOMA; PROLYL HYDROXYLASE;
D O I：
10.1016/j.semcancer.2021.10.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.
引用
收藏
页码：185 / 195
页数：11
相关论文
共 50 条
  • [41] CRISPR-Cas9 for cancer therapy: Opportunities and challenges
    Chen, Minjiang
    Mao, Aiwu
    Xu, Min
    Weng, Qiaoyou
    Mao, Jianting
    Ji, Jiansong
    CANCER LETTERS, 2019, 447 : 48 - 55
  • [42] Opportunities and challenges of carbon-based nanomaterials for cancer therapy
    Bianco, Alberto
    Kostarelos, Kostas
    Prato, Maurizio
    EXPERT OPINION ON DRUG DELIVERY, 2008, 5 (03) : 331 - 342
  • [43] Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities
    Isazadeh, Houman
    Oruji, Farshid
    Shabani, Shima
    Behroozi, Javad
    Nasiri, Hadi
    Isazadeh, Alireza
    Akbari, Morteza
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (11) : 9529 - 9543
  • [44] Targeting CDK2 in cancer: challenges and opportunities for therapy
    Tadesse, Solomon
    Anshabo, Abel T.
    Portman, Neil
    Lim, Elgene
    Tilley, Wayne
    Caldon, C. Elizabeth
    Wang, Shudong
    DRUG DISCOVERY TODAY, 2020, 25 (02) : 406 - 413
  • [45] Opportunities and challenges for anti-CD73 cancer therapy
    Zhang, Bin
    IMMUNOTHERAPY, 2012, 4 (09) : 861 - 865
  • [46] Genetically modified T cells in cancer therapy: opportunities and challenges
    Sharpe, Michaela
    Mount, Natalie
    DISEASE MODELS & MECHANISMS, 2015, 8 (04) : 337 - 350
  • [47] PET imaging of cardiac hypoxia: Opportunities and challenges
    Handley, M. G.
    Medina, R. A.
    Nagel, E.
    Blower, P. J.
    Southworth, R.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 51 (05) : 640 - 650
  • [48] Implantable smart hyperthermia nanofibers for cancer therapy: Challenges and opportunities
    Valizadeh, Amir
    Asghari, Samira
    Abbaspoor, Saleheh
    Jafari, Abbas
    Raeisi, Mortaza
    Pilehvar, Younes
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2023, 15 (06)
  • [49] Challenges and opportunities of poly(amino acid) nanomedicines in cancer therapy
    Li, Yuce
    He, Jing
    Liu, Jixiu
    Um, Wooram
    Ding, Jianxun
    NANOMEDICINE, 2024, 19 (29) : 2495 - 2504
  • [50] Nanoemulsions in Translational Research—Opportunities and Challenges in Targeted Cancer Therapy
    Srinivas Ganta
    Meghna Talekar
    Amit Singh
    Timothy P. Coleman
    Mansoor M. Amiji
    AAPS PharmSciTech, 2014, 15 : 694 - 708
12345